Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Pancreatic Stone Protein Testing Market Expansion From $1.31 Billion In 2026 To $1.77 Billion In 2030
The pancreatic stone protein testing market has witnessed substantial growth in recent years. It is projected to expand from $1.22 billion in 2025 to $1.31 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.5%. This historical growth can be attributed to the increasing prevalence of sepsis and critical care conditions, rising awareness about early disease biomarker testing, the development of hospital laboratory infrastructure, the growing adoption of immunoassay diagnostics, and increased clinical research into pancreatic and inflammatory biomarkers.
The pancreatic stone protein testing market is projected to experience substantial growth over the coming years, reaching $1.77 billion by 2030, driven by a compound annual growth rate (CAGR) of 7.8%. This expansion during the forecast period is fueled by several factors, including the increasing need for early sepsis detection tools, greater acceptance of point-of-care diagnostic testing, advancements in precision medicine and biomarker-based diagnostics, the proliferation of automated laboratory systems, and enhanced investment in critical care diagnostic innovations. Key trends anticipated for this period involve the increasing uptake of pancreatic stone protein testing as an early biomarker for identifying sepsis and systemic inflammation, a rise in the deployment of immunoassay-based diagnostic platforms for swift PSP quantification, the expanding incorporation of PSP testing into critical care and emergency diagnostic pathways, the development of point-of-care testing devices allowing quicker PSP measurement within hospitals, and a growing demand for multiplex biomarker panels that incorporate PSP alongside other inflammatory markers.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample_request?id=63819694&type=smp
#Pancreatic Stone Protein Testing Market Demand Drivers Creating New Revenue Opportunities
The increasing occurrence of hospital-acquired infections is anticipated to fuel the growth of the pancreatic stone protein testing market. These infections, known as HAIs, are conditions patients develop while receiving medical care in a hospital or healthcare facility, distinct from those present upon admission. A primary factor contributing to the rise in HAIs is increasing antimicrobial resistance, wherein microorganisms develop resistance to common antibiotics, making infections more challenging to manage in healthcare environments. Pancreatic stone protein testing aids in addressing hospital-acquired infections by enabling the prompt identification of infection and sepsis risk, thereby allowing for timely intervention and enhanced patient care within hospital settings. For example, according to the Australian Institute of Health and Welfare in November 2024, hospital-acquired complications (HACs) were recorded in 115,000 public hospitalizations (2.0%) and 34,200 private hospitalizations (0.8%) during 2022–23, with healthcare-associated infections representing the largest portion (37%), followed by delirium (13%) and cardiac complications (12%). Consequently, the growing incidence of hospital-acquired infections is propelling the expansion of the pancreatic stone protein testing market. The expansion of point-of-care testing (POCT) is anticipated to drive the growth of the pancreatic stone protein testing market moving forward. Point-of-care testing (POCT) involves medical diagnostic assessments conducted at or near the patient’s location, enabling rapid results and immediate clinical decisions without the need for central laboratory facilities. This expansion of POCT is fueled by increasing demand for quicker diagnostic outcomes, innovations in portable diagnostic technologies, and the rising necessity for efficient patient management in critical and emergency care environments. Pancreatic stone protein testing supports point-of-care testing by facilitating the swift detection of infection and sepsis risk, which enables timely clinical intervention and improves patient results in hospitals and intensive care units. For instance, in March 2025, the American Association for Clinical Chemistry (AACC), a US-based scientific society focusing on clinical laboratory science, reported that the adoption of point-of-care diagnostic testing in hospitals and outpatient settings grew by 12.4% in 2024 compared to the prior year, driven by the increasing need for rapid and decentralized diagnostic solutions. Hence, the growing prevalence of point-of-care testing (POCT) is stimulating the expansion of the pancreatic stone protein testing market.
Pancreatic Stone Protein Testing Market Segmentation: How Is The Market Structured Across Key Categories?
The pancreatic stone protein testing market covered in this report is segmented –
1) By Product Type: Assay Kits, Instruments, Reagents, Other Product Types
2) By Technology: Immunoassay Based Testing, Enzyme-Linked Immunosorbent Assay Based Testing, Rapid Diagnostic Technologies, Other Technologies
3) By Sample Type: Blood, Serum, Plasma, Other Sample Types
4) By Application: Sepsis Diagnosis, Pancreatitis Diagnosis, Other Applications
5) By End User: Hospitals, Diagnostic Laboratories, Research Institutes, Other End Users
Subsegments:
1) By Assay Kits: Enzyme Linked Immunosorbent Assay Kits, Chemiluminescence Immunoassay Kits, Fluorescence Immunoassay Kits, Rapid Diagnostic Test Kits, Multiplex Assay Kits
2) By Instruments: Immunoassay Analyzers, Clinical Chemistry Analyzers, Automated Laboratory Analyzers, Point Of Care Testing Devices, Microplate Readers
3) By Reagents: Antibodies, Calibrators, Controls, Buffers, Substrates
4) By Other Product Types: Sample Collection Kits, Quality Control Materials, Diagnostic Consumables, Laboratory Accessories, Data Management Software
Pancreatic Stone Protein Testing Market Trends Driving Strategic Industry Expansion
Leading companies in the pancreatic stone protein testing market are concentrating on developing innovative platforms, such as ultra-rapid point-of-care immunoassay platforms. This initiative aims to enable early and accurate detection of sepsis, improve the speed of clinical decision-making, and reduce patient mortality in critical care settings. Ultra-rapid point-of-care immunoassay platforms are diagnostic systems that quickly identify specific biomarkers in a patient’s sample at or near the bedside using antibody-based reactions, delivering results within minutes instead of hours or days. For instance, in October 2024, Abionic SA, a Switzerland-based in vitro diagnostics company, received approval from the U. S. Food and Drug Administration (FDA) for its IVD CAPSULE Pancreatic Stone Protein (PSP) test. This test is designed for rapid, near-patient detection of PSP levels, facilitating the early identification of sepsis in critically ill patients. It operates on ultra-rapid point-of-care immunoassay platforms, which allow for biomarker detection at the bedside using antibody-based reactions, with results delivered within minutes.
Pancreatic Stone Protein Testing Market Competitive Landscape And Leading Companies
Major companies operating in the pancreatic stone protein testing market are Cusabio Technology Llc, Fapon Biotech Inc, BioVendor Laboratorní medicína a. s, RayBiotech Life Inc, Creative Diagnostics Inc, Abnova Corporation, Abionic SA, LASCCO SA, Abbexa Ltd
Access The Complete Pancreatic Stone Protein Testing Market Report:
https://www.thebusinessresearchcompany.com/report/pancreatic-stone-protein-testing-market-report
Pancreatic Stone Protein Testing Market Regional Analysis: Which Region Leads By Revenue?
North America was the largest region in the pancreatic stone protein testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pancreatic stone protein testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Wasay has over a decade of experience in market research, data modelling, and analytics, with prior experience at GlobalData and Decision Tree Consulting Services. At The Business Research Company , he leads research operations across syndicated studies, customized consulting engagements, and the Global Market Model platform. His professional experience includes supporting organizations such as Boston Consulting Group, KPMG, and Ernst & Young. Wasay holds a degree in Electronics and Communications Engineering, postgraduate management qualifications from International Management Institute Belgium and Indian School of Business and Entrepreneurship, and completed the Integrated Program in Business Analytics from Indian Institute of Management Indore.